Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Portugal

European Research Council grant · Finished

ENSURE Non-invasive follow-up of urinary tract cancers

Coordinator
Nova Id Fct - Associacao Para a Inovacao E Desenvolvimento Da Fct, Portugal
Runs
1 July 2022 to 30 June 2024
Status
Finished
EU funding
€150k
Total cost
—
Partners
2 organisations in 2 countries
Type
European Research Council grant
Grant agreement
101069405

What the project is doing

In the project's own words, from its summary on CORDIS.

Bladder cancer is the most common malignancy of the urinary tract with 573,000 new cases and 213,000 deaths in 2020 worldwide and affecting more men than women in a 4:1 ratio. Bladder cancer has the highest lifetime treatment costs per patient of all cancers, which is mainly attributed to the intensive follow-up procedures of patients after diagnostics and surgery. Follow-up is made recurring to extremely invasive and low-patient compliant tests.

ENSURE aims to validate the technological and business feasibility of the electronic nose technology developed in the ERC Starting Grant SCENT by establishing the proof-of-concept for the non-invasive follow-up of bladder cancer patients. To accomplish this, we will approach the project from both Technical and Business perspectives, with a perfect synergy between the research and business teams, and a close contact with clinical collaborators and stakeholders.

Topics

Who is involved

OrganisationCityCountryRole
Nova Id Fct - Associacao Para a Inovacao E Desenvolvimento Da FctCaparicaPortugalCoordinator
Day One Societa a Responsabilita LimitataRoma RmItalyParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI